Agomab Doses First Patient in Global Phase 2b NOV-ERA Study of Ontunisertib in Fibrostenosing Crohn's Disease
AGMB is trading near its 52-week low of $7.97 (11% above the low).
Summary
Agomab announced the first patient dosed in its global Phase 2b NOV-ERA study of ontunisertib in fibrostenosing Crohn's disease, triggering a €7 million milestone payment to former Origo Biopharma shareholders.
Key Events · Product Development and Regulatory · AGMB
-
First Patient Dosed in Phase 2b NOV-ERA Study
The first patient has been dosed in the global Phase 2b NOV-ERA study of ontunisertib in fibrostenosing Crohn's disease, a condition with no approved anti-fibrotic therapies.
-
Study Design and Endpoints
NOV-ERA will enroll approximately 320 patients randomized 1:1:1:1 to three ontunisertib dose levels (400/200/100 mg BID) or placebo for 52 weeks, with endoscopic passability at Week 24 as the primary endpoint.
-
€7M Milestone Payment Triggered
Study initiation triggers a €7 million payment to former Origo Biopharma shareholders under the 2021 acquisition, bringing total milestone payments to €10 million of a possible €20 million.
-
Builds on Positive Phase 2a Data
The Phase 2b initiation follows positive Phase 2a STENOVA results and long-term open-label extension safety data announced earlier in October 2026, supporting the 400 mg BID arm.
Analysis · AGMB · Life Sciences
Ontunisertib has advanced into a global Phase 2b trial for fibrostenosing Crohn's disease, a condition with no approved anti-fibrotic therapies. The study will enroll approximately 320 patients across three dose levels with a 52-week treatment period, and the primary endpoint is endoscopic passability at Week 24. This milestone triggers a €7 million payment to former Origo Biopharma shareholders, bringing total milestone payments to €10 million of a possible €20 million. The initiation follows positive Phase 2a STENOVA data and long-term open-label extension results announced earlier this month, and it positions ontunisertib as a potential first-in-class targeted anti-fibrotic treatment.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AGMB was trading at $8.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $447.7M. The 52-week trading range was $7.97 to $17.82. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.